Plasminogen activation/plasmin in rheumatoid arthritis: matrix degradation and more.
Rheumatoid arthritis (RA) is one of the most common and most debilitating joint diseases, producing high personal, social, and economic costs.(1,2) Patients with RA suffer pain and functional losses, often followed by disability and premature death. Although the etiology of RA is unknown, substantial efforts have been directed toward studying the transition of the joint from normal to diseased. The maintenance of normal joint architecture and function requires equilibrium between the synthesis and degradation of the specialized extracellular matrices that make up bone, cartilage, and tendons. In RA, the balance of tissue remodeling is disturbed,(3) and excessive proteolytic degradation of the joint matrices leads to joint destruction.(4,5) The early phase of RA is characterized by the infiltration of immune and inflammatory cells into the synovium and by hyperplasia of the fibroblasts in the synovial lining. This leads to pannus formation, cartilage breakdown, and eventual bone destruction.(1,2) Through the use of an experimental mouse model of RA, Li and colleagues(6) have implicated plasmin as an essential component of the early phase of RA, as reported in this issue of The American Journal of Pathology.
Judex
Martin O
MO
Sidney Kimmel Cancer Center, San Diego, California, USA.
Mueller
Barbara M
BM
D000818:Animals; D001172:Arthritis, Rheumatoid / Q000276:immunology / Q000378:metabolism*; D005341:Fibrinolysin / Q000378:metabolism*; D005347:Fibroblasts / Q000378:metabolism; D006801:Humans; D051379:Mice; D010958:Plasminogen / Q000378:metabolism*; D010960:Plasminogen Activators / Q000378:metabolism*; D013927:Thrombosis
D010958:Plasminogen; D010960:Plasminogen Activators; D005341:Fibrinolysin
Nat Cell Biol. 2001 Mar;3(3):267-75
11231576
Endocrinology. 1999 Nov;140(11):5030-5
10537128
Ann N Y Acad Sci. 2001;936:226-36
11460480
Am J Pathol. 2002 Mar;160(3):917-26
11891190
J Immunol. 2002 Apr 1;168(7):3577-85
11907122
Thromb Haemost. 2002 Mar;87(3):493-501
11916082
Arthritis Rheum. 2002 Apr;46(4):934-45
11953970
Nat Rev Mol Cell Biol. 2002 Mar;3(3):207-14
11994741
Arterioscler Thromb Vasc Biol. 2002 Sep 1;22(9):1421-6
12231560
Front Biosci. 2003 Jan 1;8:d1-8
12456318
J Exp Med. 2002 Dec 2;196(11):1461-71
12461081
J Clin Invest. 2003 Jan;111(1):35-41
12511586
Curr Pharm Des. 2004;10(1):39-49
14754404
Cancer Metastasis Rev. 1992 Nov;11(3-4):291-311
1423820
Physiol Rev. 1993 Jan;73(1):161-95
8419965
J Biol Chem. 1994 Feb 11;269(6):4360-6
7905877
Eur J Immunol. 2004 Apr;34(4):1208-16
15048732
J Clin Invest. 2004 Jun;113(11):1596-606
15173886
J Rheumatol. 2004 Jul;31(7):1229-37
15229936
J Biol Chem. 2004 Sep 3;279(36):37528-34
15247268
Lab Invest. 1982 Mar;46(3):321-43
7062727
Clin Physiol Biochem. 1983;1(2-5):225-84
6241121
Blood. 2001 Jun 15;97(12):3941-50
11389038
Thromb Haemost. 1999 Aug;82(2):742-7
10605777
Trends Pharmacol Sci. 2000 Mar;21(3):103-8
10689364
Thromb Haemost. 1999 Sep;82 Suppl 1:4-7
10695477
J Immunol. 2000 Apr 15;164(8):4340-7
10754334
Arthritis Rheum. 2000 Aug;43(8):1710-8
10943860
Cell Mol Life Sci. 2000 Jan 20;57(1):25-40
10949579
N Engl J Med. 2001 Mar 22;344(12):907-16
11259725
Genes Dev. 1995 Apr 1;9(7):794-807
7705657
Nat Med. 1996 Mar;2(3):287-92
8612226
Ann Rheum Dis. 1996 Dec;55(12):888-94
9014582
Coron Artery Dis. 1997 Jan;8(1):9-18
9101117
Am J Physiol. 1997 Nov;273(5 Pt 1):E996-1004
9374687
Ann Rheum Dis. 1997 Dec;56(12):705-6
9496148
APMIS. 1999 Jan;107(1):80-5
10190283
Clin Exp Rheumatol. 1999 Jul-Aug;17(4):485-98
10464565
Am J Pathol. 2005 Mar;166(3):783-92
15743790